Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Koh

Showing results (21-30 of 150) with videos related to

Pageof 15
Sort By:
Chemmedchem|August 24, 2006
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistanceArun K Ghosh, Perali Ramu Sridhar, Nagaswamy Kumaragurubaran, et al.
Clinical Lung Cancer|July 10, 2020
Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator)Akihiro Tamiya, Shun-Ichi Isa, Yoshihiko Taniguchi, et al.
The Journal of Organic Chemistry|March 31, 2004
Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitorsReiko Yanada, Yasuhiro Koh, Nobuaki Nishimori, et al.
Respirology Case Reports|September 2, 2024
Unsuccessful rechallenge with nivolumab in a patient with advanced non-small cell lung cancer who had a 6-year complete response and treatment-free period: Case reportToshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, et al.
BMC Cancer|August 18, 2018
PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissueTomoya Yokota, Masakuni Serizawa, Ayumu Hosokawa, et al.
Journal of Translational Medicine|June 3, 2014
A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in bloodMasaru Watanabe, Masakuni Serizawa, Takeshi Sawada, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2008
Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugsHirotomo Nakata, Seth M Steinberg, Yasuhiro Koh, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 23, 2003
[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine]Hiro Tatetsu, Norio Asou, Miki Nakamura, et al.
International Journal of Cancer|December 4, 2003
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cellsFumiaki Koizumi, Fumihiko Kanzawa, Yutaka Ueda, et al.
Journal of Virology|January 30, 2009
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitorsManabu Aoki, David J Venzon, Yasuhiro Koh, et al.
Pageof 15

Showing results (21-30 of 150) with videos related to

Sort By:
Pageof 15
Chemmedchem|August 24, 2006
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistanceArun K Ghosh, Perali Ramu Sridhar, Nagaswamy Kumaragurubaran, et al.
Clinical Lung Cancer|July 10, 2020
Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator)Akihiro Tamiya, Shun-Ichi Isa, Yoshihiko Taniguchi, et al.
The Journal of Organic Chemistry|March 31, 2004
Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitorsReiko Yanada, Yasuhiro Koh, Nobuaki Nishimori, et al.
Respirology Case Reports|September 2, 2024
Unsuccessful rechallenge with nivolumab in a patient with advanced non-small cell lung cancer who had a 6-year complete response and treatment-free period: Case reportToshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, et al.
BMC Cancer|August 18, 2018
PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissueTomoya Yokota, Masakuni Serizawa, Ayumu Hosokawa, et al.
Journal of Translational Medicine|June 3, 2014
A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in bloodMasaru Watanabe, Masakuni Serizawa, Takeshi Sawada, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2008
Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugsHirotomo Nakata, Seth M Steinberg, Yasuhiro Koh, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 23, 2003
[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine]Hiro Tatetsu, Norio Asou, Miki Nakamura, et al.
International Journal of Cancer|December 4, 2003
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cellsFumiaki Koizumi, Fumihiko Kanzawa, Yutaka Ueda, et al.
Journal of Virology|January 30, 2009
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitorsManabu Aoki, David J Venzon, Yasuhiro Koh, et al.
Pageof 15